$4.17-$6.31 Val, page-41

Acadia our partner for the North America rights to Trofinitide ONLY, continues to grow with market cap now US$3.939 Billion dollars. Neuren the whole is market cap US86.21 Million dollars. Thats' about 1/45th. of Acadia.
Neuren still hold rest of the world rights for Trofinitide and full rights to NNZ 2591 which together has potential to be worth more than deal already done. Pitt st. research valued NEU at $5.24/share now.(mid range)
Acadia CEO Steve Davis according to recent Simply Wall St. article is higher paid than other CEO's of similar companies so must be a go getter. What are you waiting for Steve? What Neuren has has to offer will be worth Billions. Just need to clear phase 3 for the FDA and they have said that a repeat of the phase 2 results will suffice! Plus show that you are able to make Trofinitide in quantity. Neither of those requirements should be a problem for a professional outfit like yours. Have Neuren set a price that is too big for you? Is Acadia not big enough after all?